Today, there is definitely something in the news worth celebrating. Prostate cancer, which is known to be the most deadly cancer for men in both the United States and worldwide, has been found to be on a decline, according to new research, CNN shared.
The prostate is the walnut-shaped gland that is found under the bladder. It job is to secrete seminal fluid, which provides nutrition for and allows the transport of sperm. Once diagnosed with prostate cancer, the survival rate depends heavily on how far it has already spread during the time of diagnoses. It is the second leading cause of cancer diagnoses and sixth most common cause of death from cancer among men worldwide.
According to data from the World Health Organization that was gathered based on five continents from 1980 to 2012, a positive trend is showing. Overall, this information is showing that in most parts of the world, the rate of men dying and being diagnosed with prostate cancer has either decreased or stabilized. This information was shared Tuesday at the American Association of Cancer Research meeting in Atlanta.
The lead author in this study, senior associate scientist of surveillance research at the American Cancer Society, MaryBeth Freeman, shared that, "By comparing rates from different countries, we can assess differences in detection practices and improvements in treatment. Previous studies have indicated significant variation in prostate cancer rates, due to factors including detection practices, availability of treatment, and genetic factors."
The study found a decrease is diagnoses rates in seven different countries from 2008 to 2012 as well as 33 countries showing a stabilization of prostate cancer during that time. The greatest decrease was found in the United States, results that Freeman and her colleagues found to be very encouraging.
Freeman also shared that the test they used for the study was approved by the US Food and Drug Administration back in 1986 and that the use has resulted in the US decline from the 2000s to 2015. In countries with low-income where this test is not as readily available, both diagnoses and mortality rates were higher.
While there have been limitations due to the scope of data that was collected, this study allowed them to collect information on a global scale.